Pralatrexate Patent Expiration
Pralatrexate is Used for treating patients with relapsed or refractory peripheral T-cell lymphoma. It was first introduced by Acrotech Biopharma Inc
Pralatrexate Patents
Given below is the list of patents protecting Pralatrexate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Folotyn | US7622470 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | May 31, 2025 | Acrotech Biopharma |
| Folotyn | US8299078 | Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin | May 31, 2025 | Acrotech Biopharma |
| Folotyn | US6028071 | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul 16, 2022
(Expired) | Acrotech Biopharma |
Pralatrexate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List